AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Safety of Early SGLT2i Initiation in Acute Heart Failure Admissions in Patients with Elevated Hemoglobin A1c: A Propensity-Matched Real-World Study
By Thangjui S, Rana S, Jafary Z et al.
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated robust cardiovascular and renal benefits in heart failure (HF) trials. However, landmark trials such as EMPEROR-Reduced and DAPA-HF excluded patients with HbA1c ≥10%, leaving the safety of SGLT2i initiation in uncontrolled diabetes undefined. Adverse effects of SGLT2i include euglycemic diabetic ketoacidosis (DKA), volume depletion, and hemodynamic instability, which may be amplified in the acute HF setting. Whether poor glycemic control adds incremental risk when SGLT2i are started during acute HF admission remains unclear. Methods: Adults (≥18 years) newly initiated on SGLT2i (canagliflozin, dapagliflozin, or empagliflozin) within 7 days of acute HF (AHF) admission between January 2015 and March 2025 were identified using the TriNetX US Collaborative Research Network (69 healthcare organizations). Patients were stratified by HbA1c 6.5-9.9% versus ≥10% within 3 months of admission. Patients with prior DKA were excluded. 1:1 propensity score matching (PSM) with 37 covariates was performed including demographics, cardiovascular diagnoses, medications, and laboratory values. The primary outcome was DKA (including euglycemic DKA). Secondary outcomes included all-cause mortality, HF readmissions, rehospitalization, MACCE, AKI/dialysis, AMI, and major bleeding, assessed over a 75-day follow-up window. Cox proportional hazards regression was used for survival analysis. P <0.05 was considered statistically significant. Results: Of 11,583 AHF patients initiated on SGLT2i, 2,194 pairs (HbA1c 6.5-9.9% vs. ≥10%) were compared after PSM (mean age 63, 34% female). There was no significant difference in frequency of DKA (HR 0.75, 95% CI 0.46-1.22, p=0.244), all-cause mortality (HR 1.06, 95% CI 0.79-1.43, p=0.680), HF readmissions, rehospitalization, MACCE, AKI/dialysis, AMI, or major bleeding between groups (all p>0.05). Conclusion: Early in-hospital SGLT2i initiation appears safe in AHF patients with HbA1c ≥10% and should not preclude initiation of therapy based on glycemic control alone. These findings address a critical evidence gap for a population systematically excluded from landmark trials and may help clinicians make informed decisions when initiating SGLT2i in patients with uncontrolled diabetes and acute HF. Prospective studies are warranted to confirm these findings.